

Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2020 ASH Annual Meeting — Issue 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. A real-world survival study, presented by Verstovsek and colleagues at the ASH 2020 Annual Meeting, evaluating the impact of ruxolitinib's approval on overall survival (OS) for patients with intermediate- to high-risk myelofibrosis (MF) in the United States demonstrated which of the following outcomes?**
  - a. After the approval, OS was greater for those who received ruxolitinib than for those who did not**
  - b. OS was similar among patients diagnosed before and after ruxolitinib approval
- 2. Which of the following drug types best describes the mechanism of action of navitoclax?**
  - a. Hypomethylating agent
  - b. JAK1/2 inhibitor
  - c. Bcl-2 inhibitor**
- 3. Which of the following adverse events was NOT reported in the Phase I/II extension study, presented at the ASH 2020 Annual Meeting, evaluating the long-term safety of fedratinib for patients with intermediate-or high-risk MF?**
  - a. Diarrhea
  - b. Wernicke encephalopathy**
  - c. Nausea
- 4. A reanalysis of the IMbark study evaluating imetelstat for intermediate 2- or high-risk MF in relapse or refractory to JAK inhibitors demonstrated which of the following outcomes?**
  - a. Dose-related improvement in OS, with better survival at the 9.4 mg/kg dose than the 4.7 mg/kg dose**
  - b. No correlation between OS and bone marrow fibrosis